Paul S. Gaynon spends much of his time researching Internal medicine, Acute lymphocytic leukemia, Surgery, Oncology and Cancer. His study in Gastroenterology extends to Internal medicine with its themes. The Acute lymphocytic leukemia study combines topics in areas such as Hematopoietic stem cell transplantation, Clinical trial, Hematology, Randomized controlled trial and El Niño.
His Surgery research includes themes of Infant Acute Lymphoblastic Leukemia, Leukemia, Bone marrow and Hazard ratio. His work carried out in the field of Oncology brings together such families of science as Trisomy, Childhood leukemia and Aneuploidy. His Cancer research is multidisciplinary, incorporating elements of Risk factor and Lymphoblastic Leukemia.
The scientist’s investigation covers issues in Internal medicine, Oncology, Acute lymphocytic leukemia, Cancer and Chemotherapy. His research integrates issues of Gastroenterology and Surgery in his study of Internal medicine. His Oncology research incorporates elements of Clinical trial, Childhood leukemia, Asparaginase, Lymphoblastic Leukemia and Minimal residual disease.
His Acute lymphocytic leukemia research includes elements of Immunophenotyping, El Niño, Randomized controlled trial and Bone marrow. As part of one scientific family, Paul S. Gaynon deals mainly with the area of Cancer, narrowing it down to issues related to the Pediatrics, and often Retrospective cohort study and Precursor Cell Lymphoblastic Leukemia Lymphoma. The concepts of his Chemotherapy study are interwoven with issues in Cohort and Bortezomib.
Paul S. Gaynon mostly deals with Internal medicine, Oncology, Lymphoblastic Leukemia, Leukemia and Childhood leukemia. Paul S. Gaynon has included themes like Gastroenterology and Pediatrics in his Internal medicine study. His studies in Oncology integrate themes in fields like Young adult, Childhood Acute Lymphoblastic Leukemia, Asparaginase and Toxicity.
His study in the fields of Acute leukemia under the domain of Leukemia overlaps with other disciplines such as Azacitidine. His Childhood leukemia study combines topics from a wide range of disciplines, such as Etoposide, Hematopoietic stem cell transplantation, Clinical trial and Lymphoma. His studies deal with areas such as Surgery, Bioinformatics, T cell, High Resolution Melt and Acute lymphocytic leukemia as well as Minimal residual disease.
His primary areas of study are Internal medicine, Oncology, Childhood leukemia, Leukemia and Chemotherapy. His works in Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia, Toxicity, Young adult and Induction chemotherapy are all subjects of inquiry into Internal medicine. His research in Oncology intersects with topics in Odds ratio, Minimal residual disease, Very high risk, Philadelphia chromosome and Cohort.
His Minimal residual disease study combines topics in areas such as Surgery, Cyclophosphamide, Nelarabine, Acute lymphocytic leukemia and Performance status. His work deals with themes such as Etoposide, Bone marrow and Lymphoma, which intersect with Childhood leukemia. His study explores the link between Leukemia and topics such as Myeloid that cross with problems in Multicenter study, Clinical trial and KMT2A.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
Stephen P. Hunger;Xiaomin Lu;Meenakshi Devidas;Bruce M. Camitta.
Journal of Clinical Oncology (2012)
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
M Smith;D Arthur;B Camitta;A J Carroll.
Journal of Clinical Oncology (1996)
Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
Kirk R. Schultz;W. Paul Bowman;Alexander Aledo;William B. Slayton.
Journal of Clinical Oncology (2009)
Outcome of treatment in children with philadelphia chromosome-positive acute lymphoblastic leukemia
M Arico;MG Valsecchi;B Camitta;M Schrappe.
The New England Journal of Medicine (2000)
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.
Wendy Stock;Mei La;Ben Sanford;Clara D. Bloomfield.
A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a children's Cancer Group Study
Vassilios I. Avramis;Susan Sencer;Antonia P. Periclou;Harland Sather.
Factors Influencing Survival After Relapse From Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
Kim Nguyen;Meenakshi Devidas;Su-Chun Cheng;Mei La.
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)
Kirk R. Schultz;D. Jeanette Pullen;Harland N. Sather;Jonathan J. Shuster.
Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.
James B. Nachman;Harland N. Sather;Martha G. Sensel;Michael E. Trigg.
The New England Journal of Medicine (1998)
Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region
Ching-Hon Pui;Paul S Gaynon;James M Boyett;Judith M Chessells.
The Lancet (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: